PAVmed and Lucid to Hold Joint Business Update Conference Call on November 16, 2021
03 November 2021 - 1:30PM
Business Wire
Company conference call and webcast at 4:30PM
EDT
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly
differentiated, multi-product, commercial-stage medical device
company, and its major subsidiary Lucid Diagnostics Inc. (Nasdaq:
LUCD), a cancer prevention medical diagnostics company today
announced that the companies will host a joint business update
conference call on Tuesday, November 16, 2021, at 4:30 PM EDT.
During the call, Lishan Aklog, M.D., Chairman and Chief Executive
Officer of the companies, will provide a business update including
an overview of the Company’s near-term milestones and growth
strategy. In addition, Dennis McGrath, the companies’ Chief
Financial Officer, will discuss the companies’ third quarter 2021
financial results.
To access the conference call, U.S.-based listeners should dial
877-407-3982 and international listeners should dial 201-493-6780.
All listeners should provide the operator with the conference call
name “PAVmed, Inc. Business Update Conference Call” to join.
Individuals interested in listening to the live conference call via
webcast may do so by visiting the investor relations section of the
Company’s website at www.pavmed.com.
Following the conclusion of the conference call, a replay will
be available for one week and can be accessed by dialing
844-512-2921 from within the U.S. or 412-317-6671 from outside the
U.S. To access the replay, all listeners should provide the
following pin number: 1374402. The webcast will be available for
replay on the investor relations section of the Company’s website
at www.pavmed.com.
About PAVmed & Lucid
PAVmed Inc. is a highly differentiated, multi-product,
commercial-stage medical technology company with a diversified
product pipeline addressing unmet clinical needs encompassing a
broad spectrum of clinical areas with attractive regulatory
pathways and market opportunities. Its major subsidiary, Lucid
Diagnostics Inc. (Nasdaq: LUCD), markets the first and only
commercial tools for widespread early detection of esophageal
precancer and cancer – the EsoGuard® Esophageal DNA Test and
EsoCheck® Esophageal Cell Collection Device. Its GI Health division
also includes the complementary EsoCure™ Esophageal Ablation Device
with Caldus™ Technology. Another major subsidiary, Veris Health
Inc., is a digital health company developing the first intelligent
implantable vascular access port with biologic sensors and wireless
communication to improve personalized cancer care through remote
patient monitoring. Its Minimally Invasive Interventions division
markets its CarpX® Minimally Invasive Device for Carpal Tunnel
Syndrome. Other divisions include Infusion Therapy (PortIO™
Implantable Intraosseous Vascular Access Device and NextFlo™
Intravenous Infusion Set), and Emerging Innovations (non-invasive
laser-based glucose monitoring, pediatric ear tubes, and mechanical
circulatory support). For more information, please visit
www.pavmed.com, follow us on Twitter, connect with us on LinkedIn,
and watch our videos on YouTube.
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage,
cancer prevention medical diagnostics company, and subsidiary of
PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of
patients with gastroesophageal disease (GERD), also known as
chronic heartburn, who are at risk of developing esophageal
precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test,
performed on samples collected in a brief noninvasive office
procedure with its EsoCheck® Esophageal Cell Collection Device, is
the first and only commercially available diagnostic test capable
of serving as a widespread screening tool to prevent cancer and
cancer deaths through early detection of esophageal precancer in
at-risk GERD patients. EsoGuard is commercialized in the U.S. as a
Laboratory Developed Test (LDT). EsoCheck is commercialized in the
U.S. as a 510(k)-cleared esophageal cell collection device.
EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device
designation and is the subject of two large, actively enrolling,
international multicenter clinical trials to support FDA PMA
approval. Lucid is building a network of Lucid Test Centers where
at-risk GERD patients can undergo the EsoCheck procedure for
EsoGuard testing.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements, based upon the current beliefs and expectations of
PAVmed’s management, are subject to risks and uncertainties, which
could cause actual results to differ from the forward-looking
statements. Risks and uncertainties that may cause such differences
include, among other things, the ability to complete the initial
public offering of Lucid; volatility in the price of PAVmed’s
common stock, Series W Warrants and Series Z Warrants; general
economic and market conditions; the uncertainties inherent in
research and development, including the cost and time required
advance PAVmed’s products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and
results from PAVmed’s preclinical studies; whether and when
PAVmed’s products are cleared by regulatory authorities; market
acceptance of PAVmed’s products once cleared and commercialized;
our ability to raise additional funding and other competitive
developments. PAVmed has not yet received clearance from the FDA or
other regulatory body to market many of its products. The Company
has been monitoring the COVID-19 pandemic and its impact on our
business. The Company expects the significance of the COVID-19
pandemic, including the extent of its effect on the Company’s
financial and operational results, to be dictated by, among other
things, the success of efforts to contain it and the impact of
actions taken in response. New risks and uncertainties may arise
from time to time and are difficult to predict. All of these
factors are difficult or impossible to predict accurately and many
of them are beyond PAVmed’s control. For a further list and
description of these and other important risks and uncertainties
that may affect PAVmed’s future operations, see Part I, Item IA,
“Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K
filed with the Securities and Exchange Commission, as the same may
be updated in Part II, Item 1A, “Risk Factors” in any Quarterly
Report on Form 10-Q filed by PAVmed after its most recent Annual
Report. PAVmed disclaims any intention or obligation to publicly
update or revise any forward-looking statement to reflect any
change in its expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211103005626/en/
Investors Lisa DeScenza
LaVoieHealthScience (617) 351-0243
ldescenza@lavoiehealthscience.com
Media Kristi Bruno
LaVoieHealthScience (617) 865-3940
PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Apr 2023 bis Apr 2024